Rheumatology
Conference Coverage
Hip fractures likely to double by 2050 as population ages
Greater efforts “are needed to prevent hip fractures and improve the treatment gap and post-fracture care, especially in men and the oldest old...
Conference Coverage
Crystal bone algorithm predicts early fractures, uses ICD codes
This algorithm looks promising and would alert clinicians to often-missed patients with high fracture risk who need to be investigated for...
Conference Coverage
COX-2, TNF inhibitor combo appear to have limited role in reducing axSpA spinal damage progression
Despite no statistical significance, there was a strong numerical signal of reduction in spinal structural damage of adding in a selective COX-2...
Conference Coverage
Bimekizumab effective for axSpA with or without prior TNFi treatment
Data after 24 weeks of treatment with bimekizumab in patients with nonradiographic and radiographic axial spondyloarthritis show good responses in...
From the Journals
Should patients with PsA or ankylosing spondylitis with axial disease be ‘lumped’ or ‘split’?
Patients with isolated axial psoriatic arthritis (PsA) were older at diagnosis, more likely to have psoriatic nail lesions, and less likely to...
From the Journals
Inhaled, systemic steroids linked to changes in brain structure
New research adds to the growing body of evidence suggesting that glucocorticoids have significant effects on the brain, which could explain their...
Feature
Medicare drug changes ought to benefit rheumatology patients
A new federal law may soon help people taking costly drugs for rheumatologic diseases, some of which may eventually fall subject to Medicare...
From the Journals
Autoimmune disease patients’ waxing, waning response to COVID vaccination studied in-depth
Patients with immune-mediated inflammatory diseases have weaker vaccine-induced immunity to COVID but are able to build a humoral immune response...
Conference Coverage
Rivaroxaban outmatched by VKAs for AFib in rheumatic heart disease
A striking and unexpected reduction in death with the use of predominantly warfarin was just one of the many surprises delivered by the INVICTUS...
Conference Coverage
ALL-HEART: No benefit of allopurinol in ischemic heart disease
Allopurinol failed to affect a composite of nonfatal MI, nonfatal stroke, or CV death, in a randomized trial that was ‘definitively neutral’ in...
From the Journals
Olokizumab proves noninferior to adalimumab for RA in phase 3 trial
The manufacturer of olokizumab is expected to file for approval in the United States early next year, and the drug could add a new option for...